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a b s t r a c t
Patients with cardiac implantable electronic devices (CIEDs) have been followed with periodic clinic
visits. The number of patients with CIEDs has been increasing and CIEDs have become more complex.
The workload of both medical staff and patients for CIED follow-up has also been increasing. Remote
monitoring (RM) technology has undergone many developments, and RM has been used since 2008 in
Japan. The beneﬁts of RM are evident, but there are also problems with the technology. Different systems
and various skills are required for RM management compared to conventional follow-up methods.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Patients with cardiac implantable electronic devices (CIEDs)
have been followed with periodic clinic visits and have received
direct interrogation by a programmer which checks the battery,
lead impedance, sensing amplitude, pacing threshold, and
arrhythmic events. The number of patients with CIEDs has been
increasing and CIEDs have become more complex. Follow-up
frequency varies depending on the facility, physician preference,
and available resources. Checks at clinics every 3–6 months have
been recommended with increased frequency in response to
product advisories and recalls [1]. The workload of both medical
staff and patients for CIED follow-up has also been increasing.
Technology-assisted medicine has provided many beneﬁts.
Remote monitoring (RM) technology has undergone many devel-
opments from the original transtelephonic monitoring of pace-
makers for battery levels to currently available CIEDs with wireless
telemetry capabilities. Various developments have occurred over
the past decade, from fax reports to a social networking service
system, from wired interrogation to wireless interrogation, and
from one-direction transmission to bidirectional transmission. In
Japan, RM has been used since 2008. Currently, 5 CIED companies
in Japan use RM, and 27,700 patients in total have been followed
as of December 2013. Because RM is a new technology, it has both
beneﬁts and problems.
2. Technological aspects of remote monitoring
RM data are transmitted from CIEDs to a transmitter station
(Fig. 1) either by wired or wireless communication. Two types of
transmitters exist: stationary and mobile transmitters. Only sta-
tionary transmitters are used in Japan. In addition to scheduled
data transmission, alert-triggered data can be transmitted depend-
ing on the CIED [2]. Such a transmitter is linked by a telephone line
to a central secure server website to store the transmitted data for
further analysis. Companies use various telephone line types,
including analog landlines, digital landlines, and a global system
for mobile communications (GSM) network. It is sometimes
difﬁcult to set up a landline transmitter because a cable must
connect the transmitter and the landline connector. Since RM data
are likely to be transmitted at night, the transmitter should be set
up in the bedroom rather than the living room. However, in
traditional Japanese homes, there are no landline connectors in
bedrooms. A GSM transmitter would be appropriate for such
homes. After successful transmission of RM data, medical staff
can check detailed RM data on a website from anywhere. The
volume and nature of transmitted data are almost the same as
those of the data obtained from direct interrogation. Medical staff
can receive alert notiﬁcations by fax, SMS, voice message, or email.
Occasionally, we can receive precise RM data immediately follow-
ing an event such as appropriate implantable cardioverter deﬁ-
brillator (ICD) therapy, inappropriate ICD therapy, and CIED
abnormality. Medical staff can also manually or automatically
activate message calls to patients to remind them of abnormalities.
However, since elderly patients may be unaware of an abnormal
signal, a telephone call may be necessary to notify them of
abnormalities. The Table 1 shows RM characteristics by company.
3. Remote monitoring advantages
3.1. Reduced workload and costs associated with CIED follow-up for
patients and medical services
RM can reduce the workload associated with CIED follow-up.
Before RM became available, patients with CIEDs had to visit
hospitals for periodic CIED checks. It is burdensome for patients
living in rural areas to visit hospitals for CIED interrogation.
Visiting hospitals is also burdensome for patients' families,
because about half of the patients must be escorted by family
members, primarily the patients' children, who must take time off
work to escort the patients. It is also becoming difﬁcult to make
appointments for CIED checks because of the increasing number of
patients with CIEDs caused by the aging society and expanded
indications for CIED implantation. Patients must spend several
hours and sometimes even half a day in the hospital to have their
CIEDs checked, but the rate of intervention is very low [3].
However, the burden of visiting a hospital is greatly reduced by
using RM. RM use reduces the burden of overloaded clinics and
saves valuable time and resources. Varma et al. [4] reported that
RM reduced total in-hospital CIED evaluations by 45% without
affecting morbidity. In their study, 1339 patients with high-energy
CIEDs were randomized 2:1 to home monitoring (HM) or conven-
tional follow-up. Thirty-one patients in the HM group (3.4%) and
21 patients in the conventional group (4.9%) died (P¼0.226). The
overall adverse event rate was 10.4% for HM versus 10.4% for
conventional care over 12 months (non-inferiority Po0.005,
1-sided; Po0.010, 2-sided) (Fig. 2). Crossley et al. [5] also reported
that wireless RM with automatic clinician alerts was associated
with a signiﬁcant reduction in mean length of cardiovascular
hospital stay. The CONNECT (Clinical Evaluation of Remote Noti-
ﬁcation to Reduce Time to Clinical Decision) study was a multi-
center, prospective, randomized study that included 1997 patients
with high-energy CIEDs who were followed for 15 months. The
study revealed a decrease in mean length of stay per cardiovas-
cular hospitalization visit from 4.0 days in the in-ofﬁce arm to
3.3 days in the remote arm (P¼0.002). Hindricks et al. [6] reported
that in prophylactic ICD recipients with automatic daily RM,
extension of the 3-month in-ofﬁce follow-up interval to 12 months
appeared to safely reduce the ICD follow-up burden during a 27-
month period after implantation. The 12-month interval resulted
in a major reduction in total number of in-ofﬁce ICD follow-ups
(1.60 vs. 3.85 per patient-year; P¼0.001). No signiﬁcant difference
was found between the 2 groups in mortality, hospitalization rate,
or hospitalization length during the 2-year observation period.
Landolina et al. [7] reported that RM reduces the number of
emergency department/urgent ofﬁce visits and total healthcare
use in patients with high-energy CIEDs. Thus, introducing RM in
patients with high-energy CIEDs can safely reduce the ofﬁce visit
burden.
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In patients with pacemakers, RM also reduces the workload
associated with CIED follow-up. Mabo et al. [8] reported that RM
was a safe alternative to conventional care and signiﬁcantly
decreased the number of ambulatory visits during long-term
follow-up of permanently paced patients. Over 18.3 months of
follow-up, 17.3% of the patients in the RM group and 19.1% of the
patients in the control group experienced at least one major
adverse event (non-inferiority Po0.01). The number of interim
ambulatory visits in the active group was 56% lower (Po0.001)
than that in the control group. Halimi et al. [9] reported that early
discharge with RM after pacemaker implantation or replacement
was safe and facilitated patient monitoring in the month following
the procedure. Folino et al. [10] reported that remote follow-up of
pacemakers is a reliable, effective, and cost-saving procedure in
elderly, debilitated patients.
Patients are satisﬁed with RM both in terms of its ease of use
and continuous connection to the follow-up center [7,11]. Land-
olina et al. [7] reported a more favorable change in quality of life
from the baseline to the 16th month in patients with RM
compared to patients in the control group (P¼0.026). RM has
great beneﬁts for the patient's peace of mind, psychological well-
being, and safety, especially following an advisory, and is therefore
considered an important alternative to conventional follow-up
[12–15]. Raatikainen et al. [16] examined physicians' and nurses'
time required for follow-up by ofﬁce visit and RM. The physicians'
time required to review RM data was signiﬁcantly shorter than the
time needed to complete CIED follow-up visits in the clinic
(8.474.5 vs. 25.8717.0 min, Po0.001). Nurses also spent more
time on ofﬁce visits than on RM follow-up (45.3730.6 vs.
9.3715.9 min, Po0.001). Thus, RM is cost-effective [10,16,17].
During an ofﬁce visit, RM data are also used instead of direct
interrogation. By checking RM data before the patient visits, the
time required for direct interrogation and intervention can be
reduced, especially in patients with problems. Determining the
cause of a problem and how it should be managed can take time. If
a problem is ﬁrst detected during an ofﬁce visit, the patient may
have to wait for a long time until the problem is resolved.
However, this would not be the case if the problem is detected
and resolved before the patient visits. RM causes signiﬁcantly
fewer stresses than conventional follow-up.
3.2. Early detection of clinical events by remote monitoring
RM can detect various clinical events earlier than conventional
follow-up. Data obtained from direct interrogation can be detected
remotely from patients at home. With automatic RM, various
events can also be detected immediately. Varma et al. [4] reported
more rapid detection of actionable events by RM than by conven-
tional monitoring in patients with high-energy CIEDs. The median
period from onset to physician evaluation of combined ﬁrst atrial
ﬁbrillation (AF), ventricular tachycardia (VT), and ventricular
ﬁbrillation (VF) events with RM was 1 day, which was much
shorter than the median period of 35.5 days with conventional
care (AF: median, 5.5 vs. 40; interquartile range, 1–51.25 vs.
Table 1
Comparison of remote monitoring systems among 5 companies.
Medtronic CareLink® Biotronik Home
Monitoring®
St. Jude Medical
Merlin.net™
Boston Scientiﬁc Latitude® Sorin
SMARTVIEW™
Transmitter CareLink Monitor CardioMessenger Merlin@Home LATITUDE Communicator SMARTVIEW
monitor
Communication
between device and
transmitter
Wireless or Wired Wireless Wireless Wired Wireless
Data transmitter Landline Landline and global system
for mobile
communications
Landline and global
system for mobile
communications
Landline Landline
Recommended setup
location
Bedroom Bedroom Bedroom Anywhere Bedroom
Effective range to
communicate
between device and
transmitter
3m 2m 3m – 2m
Frequency of
transmission
Scheduled FU; alert events;
on patient demand
Scheduled FU; daily FU;
alert events
Scheduled FU; alert
events
Scheduled FU, weekly check,
on patient demand
Scheduled FU;
alert events; on
patient demand
Time required for data
transmission
About 5 min About 5 min About 5 min About 2 min About 5 min
Matching between
device and
transmitter
Unnecessary for special
workload
Unnecessary for special
workload
Pairing between
device and
transmitter
Pairing between device
and transmitter
Pairing between
device and
transmitter
Time zone for communication between device
and transmitter
Scheduled FU AM 0:00–1:30 Time set on device (usually
midnight), once per day
AM 2:00–4:00 AM 7:00 (button
blinking on and off)
AM 0:00–5:00
Alert events Once per 3h Once per 76 min Only AM 2:00–4:00 – AM 0:00–5:00
Feedback to patient via
transmitter
Conﬁrmation for successful
interrogation and transmission
LED indicating normal
status or call to clinic
LED indicating call to
clinic, automated
phone calls
Automatic instructive
text messages on LCD
screen and action light
–
Synchronism between
transmiter and
server
Once per 15 days None Once per 7 days Once per 8 days Once Per 7 days
Others Multiuser access capable
special monitor (Express),
OptiVol lung ﬂuid status alert,
any already implanted devices
available for RM
Digital data export
capability intrathroracic
impedance measurement
CoRVUE ﬂuid status
alert ST level
measurement
Body weight and blood pressure
monitoring capability wireless
communication is not available
in Japan, instead of west countries
–
N. Nishii / Journal of Arrhythmia 30 (2014) 395–412 397
15.5–59; VT: median, 1 vs. 28; interquartile range, 1–6 vs. 6.5–
69.25; VF: median, 1 vs. 36; interquartile range, 1–7 vs. 10–75;
supraventricular tachycardia [SVT]: median, 2 vs. 39; and inter-
quartile range, 1–19.5 vs. 8.5–69). RM also detected clinically
asymptomatic (silent) problems early for combined ﬁrst AF, VT,
VF, or SVT events (median, 1 vs. 41.5; interquartile range, 1–6 vs.
10.5–70.25) (Fig. 4, bottom). System-related problems occurred
infrequently (RM group, 14 vs. conventional group, 3). These
problems included an elective replacement indicator (1 RM
patient vs. 0 conventional patients) and atrial/ventricular lead
out-of-range impedance (13 RM patients vs. 2 conventional
patients). Statistical comparison was not possible because of the
low incidence (Fig. 3). Crossley et al. [5] reported that wireless RM
with automatic clinician alerts signiﬁcantly reduced the time to a
clinical decision in response to clinical events compared with that
in standard ofﬁce visits. The median time from a clinical event to
clinical decision per patient was reduced from 22 days in the ofﬁce
arm to 4.6 days in the RM arm (Po0.001). Landolina et al. [7]
reported that the time from an ICD alert condition to data review
was reduced from 24.8 days in the standard arm to 1.4 days in the
remote arm (Po0.001). Additionally, in patients with pacemakers,
Mabo et al. [8] reported that the median delay in medical
intervention with inter-quartile was 17 (4–48) days in the RM
group vs. 139 (33–201) days in the control group, representing a
mean 117-day gain in event detection (P¼0.001). Thus, in patients
with CIEDs, RM can detect various events earlier than conventional
follow-up. Conversely, it is necessary to assess whether earlier
detection of events results in clinical beneﬁts for patients with RM
or whether earlier detection of events excessively increases ofﬁce
visits, which may reduce clinical beneﬁts. One study showed that
early event detection may contribute to clinical beneﬁts. ECOST
[18] showed that patients with RM had 52% fewer inappropriate
shocks, fewer hospital admissions for inappropriate shocks (3 vs.
11, P¼0.02), and 76% fewer capacitor charges, leading to longer
battery life.
3.3. Possible reduction in mortality by remote monitoring
RM may reduce mortality in patients with CIEDs. Saxon et al.
[19] reported that RM is associated with excellent survival. For
Fig. 1. Pictures of the unique transmitters from each company.
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69556 ICD and cardiac resynchronization therapy with deﬁbrilla-
tor (CRT-D) patients with RM registered in a network, 1- and
5-year survival rates were higher than those in 116,222 patients
who received CIED follow-up in ofﬁce visits (50% reduction;
Po0.0001) (Fig. 4). Klersy et al. [20] reported that RM confers a
signiﬁcant protective clinical effect in patients with chronic heart
failure (HF) compared with usual care. In total, 6258 patients and
2354 patients were included in randomized controlled trials
(RCTs) and cohort studies, respectively. The median follow-up
periods were 6 months for RCTs and 12 months for cohort studies.
Both RCTs and cohort studies showed that RM was associated with
signiﬁcantly fewer deaths (RCTs: relative risk [RR]: 0.83, P¼0.006;
cohort studies: RR: 0.53, Po0.001) and hospitalizations (RCTs: RR:
0.93, P¼0.030; cohort studies: RR: 0.52, Po0.001). Although there
is no clear evidence that RM reduces mortality, RM may have such
beneﬁts.
3.4. Easy access to database systems
RM provides easy access to database systems. Classically, CIED
data have been stored on paper in health records. Much time has
been needed to gather, analyze, and research CIED data. However,
RM data are stored in a ﬁrmly protected server and can be easily
downloaded, resulting in reduced workload associated with
research. RM is also helpful for checking a setting in a situation
without a programmer. Precise setting data can be easily down-
loaded from the server.
4. What is obtained by remote monitoring? How should
we act?
RM has many beneﬁts. However, the total volume of RM data is
extensive, and we have to understand what data are important
and where the important data are located. Here, we describe what
is obtained by RM and how we should act based on RM data.
However, some suggestions may be limited to recommendations
without any evidence because the obvious evidence based on CIED
information is scarce.
4.1. Arrhythmic events
Arrhythmic events, particularly supraventricular arrhythmic
events, are frequently reported in RM data [3,5,21].
Fig. 2. Number of ofﬁce visits per patient and adverse event-free survival rates in
the control and Home Monitoring groups. (A) Cumulative hospital-based encounter
for implantable cardioverter deﬁbrillator evaluations (sum total of scheduled plus
unscheduled). Before the 3-month window (90730 days), these consisted of
unscheduled visit evaluations. After the scheduled 3-month in-person device check
clinic visits for both groups, there is a progressive divergence of curves. In the
Home Monitoring (HM) group, the slow rise in the curve reﬂects the incidence of
unscheduled evaluations. (B) There was no difference in safety between conven-
tional and HM-based follow-up.
Fig. 3. Periods of event onset to evaluation in the control and Home Monitoring groups. Home Monitoring enabled earlier physician evaluation of arrhythmias (left) and
silent events (right). AF¼atrial ﬁbrillation, VT¼ventricular tachycardia, VF¼ventricular ﬁbrillation, and SVT¼supraventricular tachycardia.
Fig. 4. Survival comparison on and off the network by device type. For both
implantable cardioverter deﬁbrillator (ICD) and cardiac resynchronization ther-
apy with deﬁbrillator (CRT-D) recipients, annual and total survival rates were
signiﬁcantly better for patients who were transmitting device information to the
network.
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4.1.1. Real-time electrocardiogram
We can recognize real-time intracardiac electrocardiogram
(ECG) at the time of data transmission. Real-time ECG is useful
because we can compare the intracardiac ECG in arrhythmic
events to that in stable conditions. The morphology of sinus
rhythm is useful for deciding whether an arrhythmic event is a
supraventricular or ventricular arrhythmia.
4.1.2. Premature ventricular contractions
In almost all CIEDs, the premature ventricular contraction
(PVC) frequency is recorded. Emergency action for PVC events is
not necessary. If antiarrhythmic drugs are administered for PVC,
the PVC counter is useful to judge the effect of therapy. However,
the PVC counter is not always precise. CIEDs might misrecognize
PVC for premature atrial contraction or T waves because of an
atrial blanking or atrial refractory period. Thus, the accuracy of
CIEDs is thought to be inferior to that of Holter ECG.
4.1.3. AF
If an atrial lead is implanted, RM can detect AF. Intervention is
not needed for AF events in patients in whom AF has been
detected and anticoagulant drugs have been administered. How-
ever, in patients without a history of AF, we can start anticoagulant
drugs early and prevent stroke. There are both symptomatic and
asymptomatic patients with paroxysmal AF (PAF). It is sometimes
difﬁcult to detect AF in asymptomatic patients with paroxysmal
AF. However, patients with CIEDs are continuously monitored and
AF is likely to be detected [22].
Some studies have examined the interaction of AF events detected
by CIEDs and stroke. Capucci et al. [23] reported that patients with
longstanding AF 424 h had a 3-times higher risk of stroke than did
control patients. Boriani et al. [24] reported that implementation of
CIED data on AF presence/duration/burden can contribute to improved
clinical risk stratiﬁcation. Glotzer et al. [25] reported that thromboem-
bolic event (TE) risk is a quantitative function of atrial tachycardia (AT)/
AF burden and that AT/AF burden 45.5 h on any of 30 prior days
appeared to double TE risk. The TREND study was a prospective,
observational study for patients with 41 stroke risk factor (HF,
hypertension, age 465 years, diabetes, and prior TE) who received
implantation of pacemakers or deﬁbrillators that monitor AT/AF
burden (deﬁned as the longest total AT/AF duration on any given
day during the prior 30-day period). AT/AF burden subsets were
deﬁned as zero, low (o5.5 h [median duration of subsets with
nonzero burden]), and high (Z5.5 h). Adjusted hazard ratios (95%
conﬁdence intervals [CIs]) in the low and high burden subsets were
0.98 (0.34–2.82, P¼0.97) and 2.20 (0.96–5.05, P¼0.06), respectively.
Healey et al. [26] reported that subclinical atrial tachyarrhythmias,
without clinical AF, occurred frequently in patients with pacemakers
and were associated with a signiﬁcantly increased risk of ischemic
stroke or systemic embolism. Subclinical atrial tachyarrhythmias were
deﬁned as episodes of atrial rate 4190 beats per minute for 46min.
In total, 2580 patients were enrolled in the ASSERT study. The patients
were aged Z65 years with hypertension and no history of AF and had
recently undergone pacemaker or deﬁbrillator implantation. Subclini-
cal atrial tachyarrhythmias detected with implanted CIEDs occurred
within 3 months in 261 patients (10.1%). Subclinical atrial tachyar-
rhythmias were associated with an increased risk of clinical AF (hazard
ratio, 5.56; Po0.001) and ischemic stroke or systemic embolism
(hazard ratio, 2.49; P¼0.007). However, it is unknown whether early
intervention for patients with CIED-based AF has a clinical beneﬁt.
Attention must also be given to AF in patients with CRT.
In some patients with CRT, if AF occurs, intrinsic conduction
becomes manifest and the pacing rate of CRT decreases (Fig. 5).
AF may induce decompensated HF. Santini et al. [27] reported that
CIED-detected AT/AF is associated with worse prognoses and that
continuous CIED diagnostic monitoring and Web-based alerts may
inform the physician of AT/AF occurrence and identify patients at
risk for cardiac deterioration or patients with suboptimal rate or
rhythm control.
Fig. 5. Cardiac Compass in a patient with cardiac resynchronization therapy with a deﬁbrillator. Atrial ﬁbrillation resulted in decreases in biventricular pacing rate and
intrathoracic impedance.
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4.1.4. Non-sustained VT
Non-sustained VT (NSVT) events are frequently detected, and
detailed data such as intracardiac electrogram, AA interval, and VV
interval can be obtained (Fig. 6). However, although CIEDs can
detect NSVT, it may in fact be supraventricular tachyarrhythmia
related to an atrial blanking or atrial refractory period. It is easy to
detect and diagnose NSVT in patients with an ICD or CRT-D, but it
is sometimes difﬁcult to accurately diagnose NSVT in patients with
pacemakers because an atrial marker may not appear because of
blanking and refractoriness.
Intervention for NSVT detected by CIED depends on the
patient‘s characteristics. In patients with ICDs or CRT-Ds, special
Fig. 6. Remote monitoring data of non-sustained ventricular tachycardia in a patient with an implantable cardioverter deﬁbrillator. (A) A-A and V-V intervals during non-
sustained ventricular tachycardia (NSVT). (B) Intracardiac electrogram during NSVT.
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management does not seem necessary. NSVT events also occur in
patients with pacemakers. Faber et al. [28] reported that many
pacemaker patients present with VT and that intracardiac ECGs
and alert functions from pacemakers may enhance physicians'
awareness of patients' intrinsic arrhythmic proﬁles. Although
NSVT is detected, special care may not be needed for patients
without structural heart disease or symptoms because of their
good prognoses [29]. However, in patients with structural heart
disease, NSVT is a risk factor for sudden cardiac death [30,31], and
special care is needed. The ﬁndings in those studies were based on
Holter ECG results, and it is unknown whether arrhythmic events
detected with CIEDs are a risk. Further studies are needed.
4.1.5. VT/VF
Physicians are notiﬁed of the occurrence of VT/VF by e-mail or
an alert during RM, and they can obtain detailed information
about the VT/VF, including intracardiac electrogram, AA interval,
VV interval, and AV interval data (Fig. 7). A decision can then be
made as to whether the event is appropriate or inappropriate for
therapy (Fig. 8) and how to manage the arrhythmic event in
patients at home. Early management of an ICD storm may be
possible. However, patients with ICD storms are known to have
poor prognoses [32].
4.2. CIED malfunction
Although CIEDs are effective in patients with bradyarrhythmia
or tachyarrhythmia, they sometimes fail to operate properly. CIED
abnormality results in life-threatening events [33]. Such events
can be avoided by early detection of a CIED abnormality.
4.2.1. Battery abnormality
Batteries usually run out gradually but occasionally run out
suddenly. These events are usually asymptomatic. Some CIEDs
have a beeping sound to alert for a serious abnormality, but others
do not have such a function. Even if the CIED has this function,
elderly patients may be unaware of the beeping sound. Acute
battery depletion can result in serious events in patients totally
depending on CIEDs. In all companies, battery abnormality is set to
a red alert, and it is easy to notice on the website (Fig. 9). We have
experienced CIEDs in which battery abnormality is likely to occur.
If a battery abnormality is detected, immediate action is necessary.
4.2.2. Lead fracture
Lead abnormality is also usually asymptomatic, and patients
are unaware of it until adverse events have occurred following
lead abnormality. Pacing failure results in life-threatening events
in patients without a native beat, and ICD lead abnormality results
in a short circuit [34,35] or inappropriate ICD shock, both of which
are followed by life-threatening adverse events. In one report, ICD
shock resulted in poor prognoses [36]. Various studies have shown
that RM can detect lead abnormality earlier than conventional
follow-up [4,5,7,37]. Various methods can detect lead abnormality.
Recently available CIEDs have a function for early detection of lead
abnormality. A red or yellow alert indicates abnormalities of lead
impedance, pacing threshold, and R wave sensing. Some noise
sensing can be detected as high ventricular or high atrial episodes.
In the initial stage of lead abnormality, lead impedance is some-
times not changed. It is therefore important to analyze an
intracardiac electrogram of NSVT or AF to detect lead abnormality
(Fig. 10).
4.2.3. Electromagnetic interference
Electromagnetic interference (EMI) inﬂuences CIEDs. In con-
ventional follow-up, EMI is detected by abnormal CIED therapy
such as inappropriate ICD therapy or oversensing and by a beeping
sound. However, in RM, EMI is detected by an emergency e-mail of
VF occurrence, and RM detects EMI much earlier than conven-
tional follow-up (Fig. 11). EMI causes resetting of the CIED setting,
which is also detected early by RM.
4.2.4. Sensing or pacing threshold abnormality
Previously, A wave and R wave amplitude and pacing threshold
measurements were performed directly in ofﬁce visits. However,
recently available CIEDs have a function for automatic A wave and
R wave amplitude and pacing threshold measurements. RM can
obtain these data from patients at home, thus allowing long
intervals between ofﬁce visits. A trend graph of lead information
can also be checked on the website, which is useful for early
detection of lead abnormality. However, if various situations do
not meet the condition, the automatic measurement is canceled. In
such cases, it is necessary to check whether the function is
operating correctly.
4.3. CIED tuning
Recently available CIEDs have multiple functions to deliver
physiological pacing, minimize battery depletion, and ensure
safety. Optimal settings such as AV interval, pacing output, and
pacing mode settings may be different at implantation and during
the follow-up period.
In conventional follow-up, these settings can be detected and
adjusted only in ofﬁce visits. However, RM can obtain accurate
information from patients at home. Optimal tuning is particularly
important for patients with CRT who have poor prognoses.
4.3.1. Minimizing ventricular pacing
Newer CIEDs except for CRT devices have a function for
minimizing the ventricular pacing rate in order to reduce AF
occurrence or prevent ventricular dyssynchrony [38,39]. The
ventricular pacing rate can be seen on the website. Instead of
employing the minimizing ventricular pacing rate function, such
as MVP or VIP, the ventricular pacing rate may remain high in
some patients. In these patients, it may be reasonable to turn off
these functions to save battery power or avoid ventricular pacing
in vulnerable periods (Fig. 12).
4.3.2. Maximizing CRT pacing rate
Decreases in the CRT pacing rate can reduce the effect of CRT,
especially in patients with AF [40,41]. Newer CIEDs have a function
for maximizing the CRT pacing rate, such as ventricular sense
response or sliding AV interval, and RM can detect a low CRT
pacing rate or long ventricular sensing events. Although the AV
interval or medication can be adjusted to maximize the CRT pacing
rate in ofﬁce visits, it is not clear when the setting should be
changed for optimization. However, sufﬁcient adjustment is parti-
cularly important for non-responder patients.
4.3.3. Pacing mode optimization
Optimal pacing mode can vary during long follow-up. For
example, paroxysmal AF can develop into chronic AF. During
paroxysmal AF, the optimal pacing mode is DDD. However, after
development of chronic AF, VVI or VVIR may be appropriate. The F
wave is likely to be undersensed, which will lead to A pacing with
ventricular blanking and ventricular blanking causing ventricular
pacing in vulnerable periods, which sometimes causes life-
threatening arrhythmia (Fig. 13).
Fine-tuning may be useful in patients with CIEDs, but it is
unknown how early various settings should be changed. In the
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Fig. 7. Emergency event in a patient followed by remote monitoring. (A) An emergency e-mail showing that the patient received an ineffective maximum energy shock. (B)
Summary and intracardiac electrogram in ventricular tachycardia on the website.
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future, tuning may become easy if remote programming technol-
ogy is developed.
4.4. Physiological data
Newer CIEDs with RM provide various types of information not
only about arrhythmia but also about physiological situations,
including heart rate variability, activity, atrial pacing rate, ventri-
cular pacing rate, supraventricular arrhythmic events, ventricular
arrhythmic events, ventricular rate during AF, apnea events, body
weight, blood pressure, ST change, and intrathoracic impedance
(ITI). Although it is unclear how to manage patients based on such
information, the information can be analyzed in an integrated
fashion and the patient's status can be understood (Fig. 14).
4.4.1. Heart rate variability
Heart rate variability (HRV) is calculated from the RR interval,
which has been associated with autonomic tone. In patients with
HF, HRV is likely to be decreased and can predict mortality
[42–44]. Results of those studies were based on the RR interval
in Holter ECG data. Autonomic tone is related to sinus node, and
AA interval may be more accurate than RR interval for assessing
autonomic tone. Thus, HRV based on CIED data may be more
useful than HRV based on Holter ECG data. Landolina et al. [45]
reported that CIED-monitored HRV is useful for identifying, early
after implantation, patients with a low likelihood of long-term
beneﬁts from CRT and at high risk for cardiovascular events.
Adamson et al. [46] reported that HRV continuously measured
from an implanted CRT-D was lower in patients at high risk for
hospitalization and mortality and may be useful in the clinical
management of patients with chronic HF. Their study included 397
patients with New York Heart Association class III or IV HF.
Continuous HRV was measured as the standard deviation of
5-min median atrial–atrial intervals (SDAAMs) sensed by CIEDs.
SDAAM o50 ms when averaged over 4 weeks was associated with
increased mortality risk (hazard ratio: 3.20, P¼0.02), and SDAAMs
were persistently lower over the entire follow-up period in
patients who required hospitalization or in patients who died.
HRV has also predicted sudden death in patients with ischemic
heart disease but not in patients with non-ischemic heart disease
[42,47–49].
Fig. 8. T wave oversensing detected by remote monitoring. Intracardiac electrogram on the website showed T wave oversensing.
Fig. 9. Elective replacement indicator event detected by remote monitoring. Battery depletion was easily noticed on the website.
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4.4.2. Activity
Almost all CIEDs have an acceleration sensor. RM can show
activity based on an acceleration sensor. In patients with HF,
activity increases with increased HRV [50,51].
4.5. Early detection of decompensated HF
HF is a common cause of hospitalization and represents a
considerable economic burden to society [52]. Despite therapeutic
advances, most of these events are readmissions for acute dete-
rioration of chronic HF [53]. Approximately 25% of discharged
patients are readmitted within 30 days, and HF is associated with a
higher rate of hospital readmission than any other medical or
surgical cause of hospitalization [54]. The ability to identify
patients at risk for hospitalization would be useful. Most HF-
related hospitalizations are related to ﬂuid accumulation, and
careful ﬂuid status surveillance and symptom monitoring are
important.
Fig. 10. Lead abnormality detected by remote monitoring. (A) Intracardiac electrogram on the website showed that a ventricular ﬁbrillation event was induced by noise. (B)
Gradual lead impedance elevation. Emergency e-mail was received. (C) Intracardiac electrogram on the website showed that a non-sustained ventricular tachycardia event
was induced by noise. (D) Sudden elevation of pacing threshold in the right ventricular lead.
Fig. 11. Electromagnetic interference detected by remote monitoring. Emergency e-mail of lead integrity alert was received. Intracardiac electrogram on the website showed
that the lead integrity alert was induced by electromagnetic interference.
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4.5.1. Telemonitoring
Clinical signs and symptoms of HF usually appear late in the
course of decompensation and are largely unreliable in routine
follow-up of patients with HF. In some reports, telemonitoring
based on symptoms and body weight failed to reduce HF hospi-
talization [55,56] (Fig. 15). There are various possible reasons why
telemonitoring failed to reduce HF hospitalization. One possibility
is that intervention based on symptoms or body weight occurs too
late, because intracardiac pressure is already elevated at the time
of symptom appearance or increased body weight [57]. Intracar-
diac pressure is increased 10–20 days before HF hospitalization.
Another possibility is low adherence rate. Chaudhry et al. [55]
found in their TRLR-HF trial that 14% of the patients who were
randomly assigned to undergo telemonitoring never used the
system and that only 55% of the patients were still using the
system at least 3 times per week in the ﬁnal week of the study
period. These ﬁndings are important given that considerable
resources, which would be difﬁcult to leverage outside a clinical
trial, were directed toward optimizing patients' engagement with
the system. Thus, a data gathering system by self-action has
limitations compared to an automatic data gathering system for
obtaining various data.
4.5.2. Direct cardiac pressure monitoring
Technology for intracardiac pressure monitoring has been
developed. One system is left atrial pressure monitoring. Ritzema
et al. [58] reported that physician-directed patient self-
management of left atrial pressure has the potential to improve
hemodynamics, symptoms, and outcomes in patients with
advanced HF. Forty patients with HF and acute decompensation
were implanted with investigational left atrial pressure monitors.
For the ﬁrst 3 months, patients and clinicians were blinded to the
readings, and treatment continued per usual clinical assessment.
Thereafter, left atrial pressure and individualized therapy instruc-
tions guided by these pressures were disclosed to the patients.
Survival without decompensation was 61% at 3 years, and events
tended to be less frequent after the ﬁrst 3 months (hazard ratio:
0.16, P¼0.012). Technology for direct pulmonary artery (PA)
pressure monitoring has also been developed. Abraham et al.
[59] reported that PA pressure monitoring resulted in a signiﬁcant
reduction in hospitalization for HF patients. During the follow-up
periods in their study (mean periods of 15 months), the treatment
group had a 37% reduction in HF-related hospitalization compared
with the control group (158 vs. 254, HR: 0.63; Po0.0001) (Fig. 16).
Thus, intracardiac monitoring may be an alternative to telemoni-
toring for reducing HF hospitalization, but such technology has not
been available so far. The most beneﬁcial point is detecting
preclinical HF before symptoms appear (Fig. 17). However, an
implanted device in the body is overwrapped by connective tissue,
which may lead to monitoring failure because the pressure
transducer may be overwrapped by connective tissue. The long-
evity of implantable pressure-monitoring devices is an unresolved
issue.
4.5.3. Intrathoracic impedance
CIEDs can now gather and store various types of data related to
HF, such as data on ventricular pacing rate, CRT delivery rate, HRV,
and ITI. We have already mentioned ventricular pacing rate, CRT
delivery rate, and HRV. Here, we will focus on ITI.
Recent studies have suggested that ITI may be a useful para-
meter to track day-to-day changes in pulmonary ﬂuid status
[60,61]. ITI was measured over time by an implanted CIED and
was correlated inversely with changes in left ventricular (LV) end
diastolic pressure in a canine HF model [60] as well as with
changes in pulmonary capillary wedge pressure (PCWP) [61] and
right ventricular pressure [62] (Fig. 18). Additionally, ITI was
negatively correlated with NT-proBNP [63]. OptiVol alert, which
is a ﬂuid status algorithm calculated from ITI, can detect impend-
ing ﬂuid accumulation at an early stage [61]. HF hospitalization
was reduced for patients with OptiVol alert. Abraham et al. [64]
reported that the sensitivity and unexplained detection rate of ITI
monitoring were superior to those seen for acute weight changes.
ITI monitoring represents a useful adjunctive clinical tool for
managing HF in patients with implanted CIEDs. Catanzariti et al.
[65] reported that the alert capability seemed to reduce the
number of HF hospitalizations by allowing timely detection and
therapeutic intervention. In their study, 532 HF patients with
implanted ICDs with an OptiVol feature were followed for 1177
months. The audible alert was on in 430 patients (ON group) and
disabled in 102 patients (OFF group). HF hospitalizations were
required for 29 patients (7%) in the ON group and for 20 patients
(20%) in the OFF group (Po0.001). The rate of combined cardiac
death and HF hospitalization was lower in patients with Alert ON
(log-rank test, P¼0.007). However, another study suggested that
the OptiVol alert could not reduce HF hospitalization [66]. van
Veldhuisen et al. reported that using an implantable diagnostic
tool to measure ITI with an audible patient alert did not improve
outcomes and increased HF hospitalizations and outpatient visits
in HF patients. They studied 335 patients with chronic HF who had
undergone implantation of ICDs alone (18%) or CRT-Ds (82%).
Patients were randomized to have information available to physi-
cians and patients as an audible alert in case of preset threshold
crossings (access arm) or not (control arm). The primary end point
was a composite of all-cause mortality and HF hospitalizations.
During a mean period of 14.975.4 months, the primary end point
occurred in 48 patients (29%) in the access arm and in 33 patients
(20%) in the control arm (HR, 1.52; P¼0.063). This was related
mainly to more HF hospitalizations (HR, 1.79; P¼0.022), whereas
the numbers of deaths were comparable (19 vs. 15; P¼0.54).
Sensitivity and positive predictive value of OptiVol alert were not
sufﬁcient to be reliable predictive parameters of HF [67], [68]. In
another report, the combination of CIED diagnostics and OptiVol
alert was necessary to increase the positive predictive value [69].
Whellan et al. [70] reported that combined HF CIED diagnostics
identiﬁed patients at higher risk of subsequent HF hospitalization
[70]. PARTNERS HF (Program to Access and Review Trending
Information and Evaluate Correlation to Symptoms in Patients
With HF) was a prospective, multicenter, observational study in
patients receiving CRT-Ds. Data from 694 CRT-D patients who
were followed for 11.772 months were analyzed. Ninety patients
had 141 adjudicated HF hospitalizations with pulmonary
Fig. 12. Change of ventricular pacing rate. (A) Pacing rate one week after
implantation (DDD). Ventricular pacing rate was very low. (B) Pacing rate at
follow-up (MVP). Pacing mode was switched from DDD to MVP before discharge.
Ventricular pacing rate was increased because atrio-ventricular conduction had
deteriorated. We noticed this event by remote monitoring.
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congestion at least 60 days after implantation. Patients with
positive combined HF CIED diagnostics had a 5.5-fold increased
risk of HF hospitalization with pulmonary signs or symptoms
within the next month (hazard ratio: 5.5, 95% CI: 3.4–8.8,
Po0.0001). OptiVol alert combined with other parameters is also
better for predicting HF events than only OptiVol alert. A meta-
analysis showed that RM in patients with HF can reduce mortality
and HF hospitalization [20], as previously mentioned.
5. Important factors at the time of informed consent
Patients beneﬁt greatly from RM, and they feel secure and safe
because they feel connected to the hospital at all times. However,
patients may have excessive expectations for RM. It is impossible
to respond to all alerts immediately for the following reasons. One
reason is medical staff. For medical staff, the workload of ofﬁce
visits can be reduced, but other workloads are increased. It is
Fig. 13. Ventricular tachycardia induced by ventricular pacing on T wave. (A) Ventricular pacing in a short coupling interval (1) induced ventricular tachycardia (VT) (2). The
implantable cardioverter deﬁbrillator terminated the VT (3). (B) Ventricular pacing in short coupling interval was introduced because of an atrial refractory period after
premature ventricular beat.
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Fig. 14. The Cardiac Compass showed a summary of various physiological information.
Fig. 15. Probability of freedom from readmission for any reason or death from any
cause. No signiﬁcant difference was seen between the 2 groups in the rate of
readmission for any reason or death from any cause.
Fig. 16. Cumulative heart failure-related hospitalizations during the entire period
of randomized single-blind follow-up. The treatment group had a 37% reduction in
heart failure-related hospitalization compared with the control group (158 vs. 254,
HR 0.63, 95% CI 0.52–0.77; Po0.0001).
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unclear whether the total workload decreases by introducing RM.
It is thus difﬁcult to respond to all alerts. To respond immediately
to all alerts, dedicated staff is necessary for 24 h a day because
alert e-mails are often received at night. We do not currently
receive sufﬁcient reimbursement for emergency events, and it is
difﬁcult to employ dedicated staff for alert e-mails. However,
patients may have the misunderstanding that medical staff can
monitor their RM data 24 h a day. Another reason is technological
problems. Even if the hospital has dedicated medical staff for
emergency events, some alerts are not sent immediately. A third
reason is occasional connection failures between the CIED and the
transmitter or between the transmitter and server. Thus, we have
to inform patients that RM is not for emergency events and that
they must visit the hospital if they have any symptoms.
It is also necessary to inform patients about security. RM data
are sent though the Internet and stored in a server. These digital
data are protected ﬁrmly, but the risk of hacking remains.
6. An RM management method example
Various workloads increase for managing RM. We have to
obtain informed consent, instruct on RM transmitter use, enroll
patients on a website, check the website for data delivery, call the
patients if data have not been delivered, download and analyze the
RM data, and inform the patients about analysis results. Thus, the
workload cannot be managed completely by doctors; other staff
members, including medical engineers, nurses and secretaries,
must also help. A team was established in 2008 in Okayama
University Hospital for managing RM. The RM team includes
doctors, medical engineers, nurses, and secretaries. There are
2 major goals for the RM team. One is to manage RM with various
staff to avoid focusing the workload on one person, and the other
is to introduce this new technology to our institute as well as other
associated hospitals.
RM team members are assigned different tasks. Mainly, doctors
obtain informed consent, nurses provide instructions on RM
transmitter use, medical engineers enroll the patients on the
website and perform the primary RM data analysis, and doctors
perform the secondary analysis. We have made one report for one
analysis. For patients in associated hospitals, we have mainly
helped to analyze RM data. Analysis reports are sent by e-mail
or fax to associated hospitals[71]. By December 2013, we had
followed more than 1000 patients with approximately 70 asso-
ciated hospitals and made more than 8000 RM reports. Only 5%
of the data required intervention by medical staff. Thus, if we focus
on only 5% of the events, we can dramatically reduce the
workload associated with CIED follow-up for both patients and
medical staff and may also reduce the cost for CIED follow-up.
7. Reimbursement considerations
RM beneﬁts not only patients with CIEDs but also medical staff.
However, reimbursement for RM is insufﬁcient for the workload of
the medical staff. We have been able to claim reimbursement for
RM since 2010 in Japan. We can now claim 5500 yen/4 months for
ofﬁce visits and 3600 yen for emergency cases. However, the
reimbursement has been limited to ofﬁce visits. This seems to be
one reason why RM has not expanded despite the great beneﬁts
for patients with CIEDs. Matsumoto reported that the reimburse-
ment fee should be higher in consideration of the workload of the
medical staff [72]. The problem may be resolved in the future.
Insufﬁcient reimbursement has also been reported in other coun-
tries [73]. One main reason is thought to be a relative paucity of
research data associated with prognosis. Although various evi-
dence of RM has been reported, it is unknown whether RM can
improve prognoses in patients with CIEDs.
8. Unresolved problems with remote monitoring
Some unresolved problems with RM remain: CIED data might
not be secure from hackers accessing a server on the Internet. In
Fig. 17. Reactive and proactive intervention for heart failure. Proactive intervention for heart failure may be useful for preventing heart failure hospitalization.
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addition, a useful database system is not available in Japan. It is
time-consuming to enter each dedicated ID and password to
access the server in each company. Moreover, to analyze RM data,
we have to create our own database, which usually requires
manual typing. It is a main source of workload for medical staff.
Further, it is unclear whether RM can improve prognosis and
whether cost-effectiveness is acceptable for clinical use. Finally,
reimbursement is insufﬁcient to manage RM in various institutes.
Fig. 18. Relationship between intracardiac pressure and intrathoracic impedance. (A) Example from one patient. Relationships between intrathoracic impedance, pulmonary
capillary wedge pressure, and net ﬂuid loss (I/O) during 4 days of intensive diuresis in the CCU. (B) Correlation between daily medians of ePAD and intrathoracic impedance.
Examples are given for 2 patients with major HF events. Correlations are shown during the whole follow-up period (r¼0.31 and 0.51) (left) and within the 1-month
period before a major HF event (r¼0.77 and 0.81) (right).
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If these problems are resolved in the future, RM may be more
accessible for both patients and medical staff.
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